Table 1.
Characteristics of participants (N = 56) and the comparison of ACE2 expression of AMs between subgroups.
| Characteristic | Number (%) | Mean (SD) ACE2a | P-valueb |
|---|---|---|---|
| Age (years) | |||
| > 65 | 25 (44.6) | 12.04 (1.25) | 0.387 |
| ≤ 65 | 31 (55.4) | 11.77 (1.10) | |
| Sex | |||
| Male | 41 (73.2) | 11.94 (1.15) | 0.580 |
| Female | 15 (26.8) | 11.74 (1.22) | |
| Overweight | |||
| BMI ≥ 24 | 25 (44.6) | 11.71 (1.27) | 0.310 |
| BMI < 24 | 31 (55.4) | 12.03 (1.07) | |
| Smoking status | |||
| Current smoker | 22 (39.3) | 12.29 (1.01) | 0.037 |
| Not current smoker | 34 (60.7) | 11.63 (1.20) | |
| COPD | |||
| Yes | 22 (39.3) | 12.18 (1.22) | 0.126 |
| No | 34 (60.7) | 11.70 (1.10) | |
| Lung cancer | |||
| Yes | 30 (53.6) | 11.84 (1.20) | 0.757 |
| No | 26 (46.4) | 11.94 (1.14) | |
| CVD | |||
| Yes | 21 (37.5) | 11.71 (0.86) | 0.333 |
| No | 35 (62.5) | 11.99 (1.31) | |
| DM | |||
| Yes | 10 (17.9) | 11.74 (1.11) | 0.657 |
| No | 46 (82.1) | 11.92 (1.18) | |
| RAAS inhibitor use | |||
| Yes | 5 (8.9) | 12.10 (1.40) | 0.673 |
| No | 51 (90.1) | 11.87 (1.15) | |
ACE2 angiotensin converting enzyme 2, AM alveolar macrophage, BMI body mass index, COPD chronic obstructive pulmonary disease, CVD Cardiovascular disease, DM diabetes mellitus, RAAS Renin–angiotensin–aldosterone.
aACE2 of AMs were measured by flow cytometry, and the mean fluorescence index value was transformed by log2.
bCalculated by Student’s t test.